risedronic acid has been researched along with Dyspepsia in 2 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 9.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 5.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Markopoulos, C | 1 |
| Tzoracoleftherakis, E | 1 |
| Polychronis, A | 1 |
| Venizelos, B | 1 |
| Dafni, U | 1 |
| Xepapadakis, G | 1 |
| Papadiamantis, J | 1 |
| Zobolas, V | 1 |
| Misitzis, J | 1 |
| Kalogerakos, K | 1 |
| Sarantopoulou, A | 1 |
| Siasos, N | 1 |
| Koukouras, D | 1 |
| Antonopoulou, Z | 1 |
| Lazarou, S | 1 |
| Gogas, H | 1 |
| Barrera, BA | 1 |
| Wilton, L | 1 |
| Harris, S | 1 |
| Shakir, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484] | 220 participants (Actual) | Observational | 2004-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for risedronic acid and Dyspepsia
| Article | Year |
|---|---|
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit | 2010 |
1 other study available for risedronic acid and Dyspepsia
| Article | Year |
|---|---|
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2005 |